WallStreetZenWallStreetZen

NASDAQ: ALKS
Alkermes PLC Stock

$24.50-0.31 (-1.25%)
Updated Jun 14, 2024
ALKS Price
$24.50
Fair Value Price
$20.34
Market Cap
$4.15B
52 Week Low
$22.01
52 Week High
$33.71
P/E
9.35x
P/B
3.3x
P/S
2.63x
PEG
N/A
Dividend Yield
4.37%
Revenue
$1.73B
Earnings
$434.43M
Gross Margin
85.3%
Operating Margin
21.69%
Profit Margin
25.2%
Debt to Equity
0.69
Operating Cash Flow
$444M
Beta
0.72
Next Earnings
Jul 22, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALKS Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALKS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALKS ($24.50) is overvalued by 20.44% relative to our estimate of its Fair Value price of $20.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALKS ($24.50) is not significantly undervalued (20.44%) relative to our estimate of its Fair Value price of $20.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALKS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more ALKS due diligence checks available for Premium users.

Be the first to know about important ALKS news, forecast changes, insider trades & much more!

ALKS News

Valuation

ALKS fair value

Fair Value of ALKS stock based on Discounted Cash Flow (DCF)
Price
$24.50
Fair Value
$20.34
Overvalued by
20.44%
ALKS ($24.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALKS ($24.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALKS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALKS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
9.35x
Industry
2.12x
Market
30.51x
ALKS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ALKS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

ALKS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.3x
Industry
2.14x
ALKS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALKS's financial health

Profit margin

Revenue
$350.4M
Net Income
$36.8M
Profit Margin
10.5%
ALKS's Earnings (EBIT) of $374.49M... subscribe to Premium to read more.
Interest Coverage Financials
ALKS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.1B
Liabilities
$869.1M
Debt to equity
0.69
ALKS's short-term assets ($1.47B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALKS's short-term assets ($1.47B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALKS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALKS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$21.1M
Investing
-$40.0M
Financing
-$17.9M
ALKS's operating cash flow ($443.76M)... subscribe to Premium to read more.
Debt Coverage Financials

ALKS vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ALKS$4.15B-1.25%9.35x3.30x
ALVO$3.75B-1.61%-6.75x-5.69x
PRGO$3.66B-1.97%-447.50x0.78x
PBH$3.21B-0.91%15.26x1.94x
HCM$3.16B-2.79%30.20x4.32x

Alkermes Stock FAQ

What is Alkermes's quote symbol?

(NASDAQ: ALKS) Alkermes trades on the NASDAQ under the ticker symbol ALKS. Alkermes stock quotes can also be displayed as NASDAQ: ALKS.

If you're new to stock investing, here's how to buy Alkermes stock.

What is the 52 week high and low for Alkermes (NASDAQ: ALKS)?

(NASDAQ: ALKS) Alkermes's 52-week high was $33.71, and its 52-week low was $22.01. It is currently -27.32% from its 52-week high and 11.31% from its 52-week low.

How much is Alkermes stock worth today?

(NASDAQ: ALKS) Alkermes currently has 169,221,311 outstanding shares. With Alkermes stock trading at $24.50 per share, the total value of Alkermes stock (market capitalization) is $4.15B.

Alkermes stock was originally listed at a price of $9.94 in Dec 31, 1997. If you had invested in Alkermes stock at $9.94, your return over the last 26 years would have been 146.48%, for an annualized return of 3.53% (not including any dividends or dividend reinvestments).

How much is Alkermes's stock price per share?

(NASDAQ: ALKS) Alkermes stock price per share is $24.50 today (as of Jun 14, 2024).

What is Alkermes's Market Cap?

(NASDAQ: ALKS) Alkermes's market cap is $4.15B, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alkermes's market cap is calculated by multiplying ALKS's current stock price of $24.50 by ALKS's total outstanding shares of 169,221,311.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.